Activin and Inhibin

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, compared with HDACs 4, 6, 8, and 10An HDAC inhibitor shown to inhibit angiogenesis and metastasis.

Enzalutamide-d 6 is a deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells.Form:Solid.

Enzalutamide-d 6 is a deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells.Form:Solid.

Enzalutamide-d 6 is a deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells.Form:Solid.

Enzaplatovir (BTA-C585) is an orally bioavailable Inhibitor for respiratory syncytial virus ( RSV ) infectionIn VitroRespiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) imposes a substantial medical burden.

Enzaplatovir (BTA-C585) is an orally bioavailable Inhibitor for respiratory syncytial virus ( RSV ) infectionIn VitroRespiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) imposes a substantial medical burden.

Enzaplatovir (BTA-C585) is an orally bioavailable Inhibitor for respiratory syncytial virus ( RSV ) infectionIn VitroRespiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) imposes a substantial medical burden.

Enzyme-IN-1 (compound 1) is a peptide-based inhibitor of N-terminal nucleophile (Ntn) hydrolases. Specifically, Enzyme-IN-1 inhibits the chymotrypsin-like activity (CT-L) of the 20S proteasome. Enzyme-IN-1 may has potential antiinflammatory

Enzyme-IN-1 (compound 1) is a peptide-based inhibitor of N-terminal nucleophile (Ntn) hydrolases. Specifically, Enzyme-IN-1 inhibits the chymotrypsin-like activity (CT-L) of the 20S proteasome. Enzyme-IN-1 may has potential antiinflammatory

EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetesIn VivoEP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit

EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetesIn VivoEP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit

EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetesIn VivoEP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit